Evidence map›Paper›PMID 29095543›Full record

ReviewJournal of magnetic resonance imaging : JMRI2018

Background, current role, and potential applications of radiogenomics.

Katja Pinker, Fuki Shitano, Evis Sala, Richard K Do, Robert J Young, Andreas G Wibmer, Hedvig Hricak, Elizabeth J Sutton, Elizabeth A Morris

Abstract readReview
In one paragraph

Review in Journal of magnetic resonance imaging : JMRI, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Imaging genomics of cancer: a bibliometric analysis and review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katja PinkerDepartment of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-2722-7331
Fuki ShitanoDepartment of Radiology, Body Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Evis SalaDepartment of Radiology, Body Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Richard K DoDepartment of Radiology, Body Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Robert J YoungDepartment of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andreas G WibmerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hedvig HricakDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elizabeth J SuttonDepartment of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-1407-7012
Elizabeth A MorrisDepartment of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

With the genomic revolution in the early 1990s, medical research has been driven to study the basis of human disease on a genomic level and to devise precise cancer therapies tailored to the specific genetic makeup of a tumor. To match novel therapeutic concepts conceived in the era of precision medicine, diagnostic tests must be equally sufficient, multilayered, and complex to identify the relevant genetic alterations that render cancers susceptible to treatment. With significant advances in training and medical imaging techniques, image analysis and the development of high-throughput methods to extract and correlate multiple imaging parameters with genomic data, a new direction in medical research has emerged. This novel approach has been termed radiogenomics. Radiogenomics aims to correlate imaging characteristics (ie, the imaging phenotype) with gene expression patterns, gene mutations, and other genome-related characteristics and is designed to facilitate a deeper understanding of tumor biology and capture the intrinsic tumor heterogeneity. Ultimately, the goal of radiogenomics is to develop imaging biomarkers for outcome that incorporate both phenotypic and genotypic metrics. Due to the noninvasive nature of medical imaging and its ubiquitous use in clinical practice, the field of radiogenomics is rapidly evolving and initial results are encouraging. In this article, we briefly discuss the background and then summarize the current role and the potential of radiogenomics in brain, liver, prostate, gynecological, and breast tumors. LEVEL OF EVIDENCE: 5 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;47:604-620.

Indexed as

Diagnostic ImagingFemaleGenomicsHumansMaleNeoplasmsbrainbreastgynecological cancerliverprostateradiogenomicsradiomics

Identifiers

PMID29095543
PMCPMC5916793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.